Elena S Diaz1, Beth Y Karlan, Andrew J Li. 1. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars-Sinai Medical Center, 8635 West 3rd Street, Suite 280W, Los Angeles, CA 90048, USA. Elena.Diaz@cshs.org
Abstract
OBJECTIVES: Obesity impacts outcome in women with epithelial ovarian cancer (EOC), although its exact role and the molecular mechanisms remain poorly defined. Adipocytes secrete leptin and adiponectin, and the leptin to adiponectin (L:A) ratio is correlated with poor survival in other malignancies. We hypothesized that the L:A ratio is associated with survival in women with EOC. METHODS: We queried the institutional tumor registry for patients with advanced stage EOC and identified a cohort of 161 women with banked fasting prediagnostic serum samples. Patients underwent cytoredutive surgery followed by platinum-based chemotherapy. Sera were assayed for leptin and adiponectin, and clinico-pathologic data were abstracted. Standard statistical tests were performed. RESULTS: 161 patients met inclusion criteria. We identified a significant correlation between BMI and leptin and the L:A ratio, but not adiponectin, in this cohort (r=0.46, 0.46, and -0.13, respectively; p=0.001, 0.001, and 0.106). Women with low L:A ratios demonstrated statistically longer disease-specific survival (57 months) compared to those with median or high levels (49 and 37 months, respectively; p=0.02). On multivariate analysis, we determined that BMI and age, but not L:A ratio, retained significance as independent prognostic factors for survival (p=0.04, 0.004, and 0.895, respectively). CONCLUSIONS: In this cohort, the L:A ratio correlated statistically with clinical outcome, but did not independently predict survival. Obesity remains a modifiable risk factor in women with EOC. Further studies are needed to determine if leptin and/or adiponectin may be potential therapeutic targets in obese women with EOC.
OBJECTIVES: Obesity impacts outcome in women with epithelial ovarian cancer (EOC), although its exact role and the molecular mechanisms remain poorly defined. Adipocytes secrete leptin and adiponectin, and the leptin to adiponectin (L:A) ratio is correlated with poor survival in other malignancies. We hypothesized that the L:A ratio is associated with survival in women with EOC. METHODS: We queried the institutional tumor registry for patients with advanced stage EOC and identified a cohort of 161 women with banked fasting prediagnostic serum samples. Patients underwent cytoredutive surgery followed by platinum-based chemotherapy. Sera were assayed for leptin and adiponectin, and clinico-pathologic data were abstracted. Standard statistical tests were performed. RESULTS: 161 patients met inclusion criteria. We identified a significant correlation between BMI and leptin and the L:A ratio, but not adiponectin, in this cohort (r=0.46, 0.46, and -0.13, respectively; p=0.001, 0.001, and 0.106). Women with low L:A ratios demonstrated statistically longer disease-specific survival (57 months) compared to those with median or high levels (49 and 37 months, respectively; p=0.02). On multivariate analysis, we determined that BMI and age, but not L:A ratio, retained significance as independent prognostic factors for survival (p=0.04, 0.004, and 0.895, respectively). CONCLUSIONS: In this cohort, the L:A ratio correlated statistically with clinical outcome, but did not independently predict survival. Obesity remains a modifiable risk factor in women with EOC. Further studies are needed to determine if leptin and/or adiponectin may be potential therapeutic targets in obesewomen with EOC.
Authors: Rikki Cannioto; Michael J LaMonte; Harvey A Risch; Chi-Chen Hong; Lara E Sucheston-Campbell; Kevin H Eng; J Brian Szender; Jenny Chang-Claude; Barbara Schmalfeldt; Ruediger Klapdor; Emily Gower; Albina N Minlikeeva; Gary R Zirpoli; Elisa V Bandera; Andrew Berchuck; Daniel Cramer; Jennifer A Doherty; Robert P Edwards; Brooke L Fridley; Ellen L Goode; Marc T Goodman; Estrid Hogdall; Satoyo Hosono; Allan Jensen; Susan Jordan; Susanne K Kjaer; Keitaro Matsuo; Roberta B Ness; Catherine M Olsen; Sara H Olson; Celeste Leigh Pearce; Malcolm C Pike; Mary Anne Rossing; Elizabeth A Szamreta; Pamela J Thompson; Chiu-Chen Tseng; Robert A Vierkant; Penelope M Webb; Nicolas Wentzensen; Kristine G Wicklund; Stacey J Winham; Anna H Wu; Francesmary Modugno; Joellen M Schildkraut; Kathryn L Terry; Linda E Kelemen; Kirsten B Moysich Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-05-06 Impact factor: 4.254
Authors: Monjri M Shah; Britt K Erickson; Tasnia Matin; Gerald McGwin; Jovana Y Martin; Laura Becca Daily; Daniel Pasko; Christen W Haygood; Janelle M Fauci; Charles A Leath Journal: Gynecol Oncol Date: 2014-09-16 Impact factor: 5.482
Authors: C M Nagle; S C Dixon; A Jensen; S K Kjaer; F Modugno; A deFazio; S Fereday; J Hung; S E Johnatty; P A Fasching; M W Beckmann; D Lambrechts; I Vergote; E Van Nieuwenhuysen; S Lambrechts; H A Risch; M A Rossing; J A Doherty; K G Wicklund; J Chang-Claude; M T Goodman; R B Ness; K Moysich; F Heitz; A du Bois; P Harter; I Schwaab; K Matsuo; S Hosono; E L Goode; R A Vierkant; M C Larson; B L Fridley; C Høgdall; J M Schildkraut; R P Weber; D W Cramer; K L Terry; E V Bandera; L Paddock; L Rodriguez-Rodriguez; N Wentzensen; H P Yang; L A Brinton; J Lissowska; E Høgdall; L Lundvall; A Whittemore; V McGuire; W Sieh; J Rothstein; R Sutphen; H Anton-Culver; A Ziogas; C L Pearce; A H Wu; P M Webb Journal: Br J Cancer Date: 2015-07-07 Impact factor: 7.640